Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C11H16N4O4 |
| Molecular Weight | 268.2691 |
| Optical Activity | ( + ) |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2
InChI
InChIKey=BMKDZUISNHGIBY-ZETCQYMHSA-N
InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m0/s1
| Molecular Formula | C11H16N4O4 |
| Molecular Weight | 268.2691 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Curator's Comment: description was created based on several sources, including http://www.accessdata.fda.gov/drugsatfda_docs/label/2014/020212s017lbl.pdf
Dexrazoxane is a cardioprotective drug used in patients with breast cancer to reduce cardiomyopathy associated with doxorubicin administration. Dexrazoxane is believed to act by two mechanisms: it inhibits DNA topoisomerase II and acts as a chelator for iron ions.
Originator
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: CHEMBL2094255 |
13.0 µM [IC50] | ||
Target ID: CHEMBL2363058 |
17.4 null [pKi] |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Secondary | ZINECARD Approved UseZinecard is indicated for reducing the incidence and severity of cardiomyopathy associated with doxorubicin administration in women with metastatic breast cancer who have received a cumulative doxorubicin dose of 300 mg/m2 and who will continue to receive doxorubicin therapy to maintain tumor control. Launch Date1995 |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2.5 h |
500 mg/m² single, intravenous dose: 500 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: DOXORUBICIN |
DEXRAZOXANE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
100% |
500 mg/m² single, intravenous dose: 500 mg/m² route of administration: Intravenous experiment type: SINGLE co-administered: DOXORUBICIN |
DEXRAZOXANE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE food status: UNKNOWN |
Doses
| Dose | Population | Adverse events |
|---|---|---|
250 mg/m2 1 times / 4 weeks multiple, intravenous MTD Dose: 250 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / 4 weeks Sources: |
unhealthy, 57 years (range: 46-76 years) Health Status: unhealthy Age Group: 57 years (range: 46-76 years) Sex: M+F Sources: |
Disc. AE: Thrombocytopenia... AEs leading to discontinuation/dose reduction: Thrombocytopenia (grade 4, 2 patients) Sources: |
900 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 900 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 900 mg/m2, 1 times / 3 weeks Sources: |
unhealthy, adult |
DLT: Neutropenia... |
600 mg/m2 1 times / 3 weeks multiple, intravenous RP2D Dose: 600 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 600 mg/m2, 1 times / 3 weeks Sources: |
unhealthy, adult |
DLT: Neutropenia... |
500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
Other AEs: Alopecia, Nausea... Other AEs: Alopecia (94%) Sources: Nausea (77%) Vomiting (59%) Malaise and fatigue (61%) Anorexia (42%) Stomatitis (34%) Fever (34%) Infection (23%) Diarrhea (21%) Injection site pain (12%) Sepsis (17%) Neurotoxicity (17%) Erythema (5%) Phlebitis (6%) Esophagitis (6%) Dysphagia (8%) Hemorrhage (2%) Extravasation (1%) Urticaria (2%) Administration site recall reaction (1%) |
500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
Other AEs: Alopecia, Nausea... Other AEs: Alopecia (100%) Sources: Nausea (51%) Vomiting (42%) Malaise and fatigue (48%) Anorexia (27%) Stomatitis (26%) Fever (22%) Infection (19%) Diarrhea (14%) Injection site pain (13%) Sepsis (12%) Neurotoxicity (10%) Erythema (4%) Phlebitis (3%) Esophagitis (3%) Hemorrhage (3%) Extravasation (3%) Urticaria (2%) Administration site recall reaction (1%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Thrombocytopenia | grade 4, 2 patients Disc. AE |
250 mg/m2 1 times / 4 weeks multiple, intravenous MTD Dose: 250 mg/m2, 1 times / 4 weeks Route: intravenous Route: multiple Dose: 250 mg/m2, 1 times / 4 weeks Sources: |
unhealthy, 57 years (range: 46-76 years) Health Status: unhealthy Age Group: 57 years (range: 46-76 years) Sex: M+F Sources: |
| Neutropenia | 4 patients DLT |
900 mg/m2 1 times / 3 weeks multiple, intravenous Highest studied dose Dose: 900 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 900 mg/m2, 1 times / 3 weeks Sources: |
unhealthy, adult |
| Neutropenia | 4 patients DLT |
600 mg/m2 1 times / 3 weeks multiple, intravenous RP2D Dose: 600 mg/m2, 1 times / 3 weeks Route: intravenous Route: multiple Dose: 600 mg/m2, 1 times / 3 weeks Sources: |
unhealthy, adult |
| Administration site recall reaction | 1% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Extravasation | 1% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Injection site pain | 12% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Neurotoxicity | 17% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Sepsis | 17% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Hemorrhage | 2% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Urticaria | 2% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Diarrhea | 21% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Infection | 23% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Fever | 34% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Stomatitis | 34% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Anorexia | 42% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Erythema | 5% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Vomiting | 59% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Esophagitis | 6% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Phlebitis | 6% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Malaise and fatigue | 61% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Nausea | 77% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Dysphagia | 8% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Alopecia | 94% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Administration site recall reaction | 1% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Neurotoxicity | 10% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Alopecia | 100% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Sepsis | 12% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Injection site pain | 13% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Diarrhea | 14% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Infection | 19% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Urticaria | 2% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Fever | 22% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Stomatitis | 26% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Anorexia | 27% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Esophagitis | 3% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Extravasation | 3% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Hemorrhage | 3% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Phlebitis | 3% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Erythema | 4% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Vomiting | 42% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Malaise and fatigue | 48% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
| Nausea | 51% | 500 mg/m2 1 times / day multiple, intravenous Recommended Dose: 500 mg/m2, 1 times / day Route: intravenous Route: multiple Dose: 500 mg/m2, 1 times / day Sources: |
unhealthy, adult Health Status: unhealthy Age Group: adult Sex: F Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Multicenter randomized phase III study of the cardioprotective effect of dexrazoxane (Cardioxane) in advanced/metastatic breast cancer patients treated with anthracycline-based chemotherapy. | 2006-04 |
|
| Matrix metalloproteinase-2 and -9 are induced differently by doxorubicin in H9c2 cells: The role of MAP kinases and NAD(P)H oxidase. | 2006-02-15 |
|
| Experimental study of dexrazoxane-anthracycline combinations using the model of isolated perfused rat heart. | 2006-02-08 |
|
| Altered responsiveness of the guinea-pig isolated ileum to smooth muscle stimulants and to electrical stimulation after in situ ischemia. | 2006-02 |
|
| Late anthracycline cardiotoxicity protection by dexrazoxane (ICRF-187) in pediatric patients: echocardiographic follow-up. | 2006-02 |
|
| Suppression of mitoxantrone cardiotoxicity in multiple sclerosis patients by dexrazoxane. | 2006-01 |
|
| Treatment of anthracycline extravasation in mice with dexrazoxane with or without DMSO and hydrocortisone. | 2006-01 |
|
| Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. | 2005-12 |
|
| Cardioprotective effect of dexrazoxane during treatment with doxorubicin: a study using low-dose dobutamine stress echocardiography. | 2005-12 |
|
| Long-term serial echocardiographic examination of late anthracycline cardiotoxicity and its prevention by dexrazoxane in paediatric patients. | 2005-11 |
|
| Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. | 2005-10-01 |
|
| Combining etoposide and dexrazoxane synergizes with radiotherapy and improves survival in mice with central nervous system tumors. | 2005-09-15 |
|
| Amifostine and dexrazoxane enhance the rapid loss of bone mass and further deterioration of vertebrae architecture in female rats. | 2005-09 |
|
| Metabolism of the one-ring open metabolites of the cardioprotective drug dexrazoxane to its active metal-chelating form in the rat. | 2005-09 |
|
| Clinical nurse specialist and evidence-based practice: managing anthracycline extravasation. | 2005-08-05 |
|
| Molecular pharmacology of the interaction of anthracyclines with iron. | 2005-08 |
|
| Monitoring cardiac function in patients receiving doxorubicin. | 2005-07 |
|
| CD95/Apo-1/Fas: independent cell death induced by doxorubicin in normal cultured cardiomyocytes. | 2005-07 |
|
| Dexrazoxane for the prevention of cardiomyopathy in anthracycline treated pediatric cancer patients. | 2005-06-15 |
|
| Prediction of genotoxicity of chemical compounds by statistical learning methods. | 2005-06 |
|
| Metabolism of the cardioprotective drug dexrazoxane and one of its metabolites by isolated rat myocytes, hepatocytes, and blood. | 2005-06 |
|
| Dexrazoxane protects against myelosuppression from the DNA cleavage-enhancing drugs etoposide and daunorubicin but not doxorubicin. | 2005-05-15 |
|
| Myocardial content of selected elements in experimental anthracycline-induced cardiomyopathy in rabbits. | 2005-04 |
|
| Gender-dependent reductions in vertebrae length, bone mineral density and content by doxorubicin are not reduced by dexrazoxane in young rats: effect on growth plate and intervertebral discs. | 2005-03 |
|
| Cardioprotective interventions for cancer patients receiving anthracyclines. | 2005-01-25 |
|
| The antitumor anthracyclines doxorubicin and daunorubicin do not inhibit cell growth through the formation of iron-mediated reactive oxygen species. | 2005-01 |
|
| The prevention and management of cardiovascular complications of chemotherapy in patients with cancer. | 2005 |
|
| Dexrazoxane : a review of its use for cardioprotection during anthracycline chemotherapy. | 2005 |
|
| Anthracycline-induced cardiotoxicity in children with cancer: strategies for prevention and management. | 2005 |
|
| Mitoxantrone treatment of multiple sclerosis: safety considerations. | 2004-12-28 |
|
| Antitumor effects of two bisdioxopiperazines against two experimental lung cancer models in vivo. | 2004-12-24 |
|
| Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells. | 2004-12-02 |
|
| Can dexrazoxane reduce myocardial injury in anthracycline-treated children with acute lymphoblastic leukemia? | 2004-11 |
|
| [Cardiac prevention: the oncologic point of view]. | 2004-11 |
|
| Evaluating the role of dexrazoxane as a cardioprotectant in cancer patients receiving anthracyclines. | 2004-11 |
|
| The iron chelating cardioprotective prodrug dexrazoxane does not affect the cell growth inhibitory effects of bleomycin. | 2004-11 |
|
| Accelerated approval of oncology products: a decade of experience. | 2004-10-20 |
|
| Concurrent therapies that protect against doxorubicin-induced cardiomyopathy. | 2004-10 |
|
| Feasibility and pharmacokinetic study of infusional dexrazoxane and dose-intensive doxorubicin administered concurrently over 96 h for the treatment of advanced malignancies. | 2004-09 |
|
| The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. | 2004-07-08 |
|
| [Dexrazoxane in patients with B-lymphomas or acute leukemias in the 2nd complete remission enables further therapy with cardiotoxic anthracyclines over recommended cumulative doses]. | 2004-06 |
|
| [Dexrazoxane and cardiotoxicity in repeatedly treated patients]. | 2004-06 |
|
| Rabbit model for in vivo study of anthracycline-induced heart failure and for the evaluation of protective agents. | 2004-06 |
|
| Dexrazoxane for anthracycline extravasation and GM-CSF for skin ulceration and wound healing. | 2004-05 |
|
| Synthesis and characterization of the biological activity of the cisplatin analogs, cis-PtCl(2)(dexrazoxane) and cis-PtCl(2)(levrazoxane), of the topoisomerase II inhibitors dexrazoxane (ICRF-187) and levrazoxane (ICRF-186). | 2004-04 |
|
| Cardiotoxicity of cytotoxic drugs. | 2004-04 |
|
| Anaphylaxis to dexrazoxane (ICRF-187) following three previous uncomplicated infusions. | 2004-02 |
|
| Iron chelators in cancer chemotherapy. | 2004 |
|
| Protection against acute adriamycin-induced cardiotoxicity by garlic: role of endogenous antioxidants and inhibition of TNF-alpha expression. | 2003-12-20 |
|
| Protein profiling in daunorubicin-induced cardiomyopathy. | 2003-09 |
Sample Use Guides
The recommended dosage ratio of dexrazoxane to doxorubicin is 10:1 (e.g., 500 mg/m2 dexrazoxane to 50 mg/m2 doxorubicin). Do not administer doxorubicin before dexrazoxane.
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 17:54:09 GMT 2025
by
admin
on
Mon Mar 31 17:54:09 GMT 2025
|
| Record UNII |
048L81261F
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Official Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Systematic Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-ATC |
V03AF02
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
||
|
NDF-RT |
N0000180854
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
||
|
FDA ORPHAN DRUG |
181103
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
||
|
FDA ORPHAN DRUG |
63291
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
||
|
WHO-VATC |
QV03AF02
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
||
|
EU-Orphan Drug |
EU/3/01/059
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
||
|
NCI_THESAURUS |
C62357
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
Z-72
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
PRIMARY | |||
|
24584-09-6
Created by
admin on Mon Mar 31 17:54:09 GMT 2025 , Edited by admin on Mon Mar 31 17:54:09 GMT 2025
|
PRIMARY | |||
|
CHEMBL1738
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
PRIMARY | |||
|
048L81261F
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
PRIMARY | |||
|
71384
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
PRIMARY | |||
|
169780
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
PRIMARY | |||
|
C1333
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
PRIMARY | |||
|
Dexrazoxane
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
PRIMARY | |||
|
100000085432
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
PRIMARY | |||
|
m9511
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
PRIMARY | Merck Index | ||
|
DB00380
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
PRIMARY | |||
|
7319
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
PRIMARY | |||
|
DTXSID3040647
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
PRIMARY | |||
|
42736
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
PRIMARY | RxNorm | ||
|
SUB07046MIG
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
PRIMARY | |||
|
048L81261F
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
PRIMARY | |||
|
7330
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
PRIMARY | |||
|
6544
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
PRIMARY | |||
|
50223
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
PRIMARY | |||
|
DEXRAZOXANE
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
PRIMARY | |||
|
839
Created by
admin on Mon Mar 31 17:54:10 GMT 2025 , Edited by admin on Mon Mar 31 17:54:10 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
RACEMATE -> ENANTIOMER |
|
||
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|
